Evidence map›Paper›PMID 28766061›Full record

ArticleApoptosis : an international journal on programmed cell death2017

Lysophosphatidic acid enhances human umbilical cord mesenchymal stem cell viability without differentiation via LPA receptor mediating manner.

Narengerile Li, Ya-Li Yan, Sachaofu Fu, Rui-Juan Li, Peng-Fei Zhao, Xi-Yuan Xu, Jing-Ping Yang, Alatangaole Damirin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. The function of GPCRs in different bone cells.International journal of biological sciences · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Zoological research · 2022
    Article
  7. Article
  8. Revisiting the role of lysophosphatidic acid in stem cell biology.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Narengerile LiDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China.
Ya-Li YanDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China.
Sachaofu FuDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China.
Rui-Juan LiDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China.
Peng-Fei ZhaoDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China.
Xi-Yuan XuDepartment of Respiratory and Critical Medicine, The Third Affiliated Hospital, Inner Mongolia Medical University, Baotou, 014010, Inner Mongolia, China.
Jing-Ping YangDepartment of Respiratory and Critical Medicine, The Third Affiliated Hospital, Inner Mongolia Medical University, Baotou, 014010, Inner Mongolia, China. yangron@sina.com.cn.
Alatangaole DamirinDepartment of Biology, College of Life Sciences, Inner Mongolia University, Hohhot, 010021, Inner Mongolia, China. bigaole@imu.edu.cn.
Inner Mongolia University · CNInner Mongolia Medical University · CN

Funding

National Natural Science Foundation of China No.31260210National Natural Science Foundation of China No. 81460021National Natural Science Foundation of China No. 8166010065
6 · The paper itself

Abstract

Human umbilical cord mesenchymal stem cells (hUC-MSCs) are potential stromal cells which are regarded as the most feasible stem cell group in cell therapy. The maintenance of cell survival without differentiation is important in cell transplantation and stem cell therapy. However, negative factors exist in cell transplantation. Lysophosphatidic acid (LPA) is a non-antigenic small molecule phospholipid which induced several fundamental cellular responses, such as cell proliferation, apoptosis and migration. In this study we aimed to explore the effects of LPA on the survival and differentiation of MSCs and its availability in cell therapy. We found that LPA stimulated hUC-MSC proliferation and protected hUC-MSCs from lipopolysaccharide (LPS) induced apoptosis. We also observed that CD29, CD44, CD73, CD90 and CD105 were expressed, whereas CD34 and CD45 were not expressed in hUC-MSCs, and these makers have no change in LPA containing medium, which indicated that LPA accelerated the survival of hUC-MSCs in an undifferentiating status. We also demonstrated that higher expressed LPAR1 involved in LPA stimulated cell survival action. LPA stimulated cell proliferation was associated with LPAR1 mediated G

Indexed as

Antigens, DifferentiationApoptosisCaspase 3Cell DifferentiationCell ProliferationCells, CulturedCell SurvivalGene Expression RegulationGene Knockdown TechniquesGTP-Binding Protein alpha SubunitsHumansLysophospholipidsMAP Kinase Signaling SystemMesenchymal Stem CellsMesenchymal Stem Cell TransplantationReceptors, Lysophosphatidic AcidAntigens, DifferentiationCaspase 3GTP-Binding Protein alpha Subunitslysophosphatidic acidLysophospholipidsReceptors, Lysophosphatidic AcidCell-surface markerCell survivalHuman umbilical cord mesenchymal stem cellsLysophosphatidic acidReceptor mediated signaling

Identifiers

PMID28766061
PMCPMC5630659
OpenAlexW2740332921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.